Second-line therapy in young patients with relapsed or refractory orbital rhabdomyosarcoma
© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd..
OBJECTIVE: Localized orbital rhabdomyosarcoma (oRMS) has an overall favourable prognosis with more than 90% of survival. Little is known about the best strategy in recurrent/refractory (R/R) cases. The purpose is to examine the characteristics of patients with R/R-oRMS, focusing on local therapy.
METHODS: This is bicentric retrospective study. Analysis is of young patients (<30 years) with R/R-oRMS who were treated from 1989 to 2018 at the Institut Curie and Gustave Roussy Cancer Campus, France.
RESULTS: Twenty-seven out of 162 patients (17%) with oRMS presented with R/R disease. 6 of these patients had alveolar RMS (22%), 3 of whom had initial parameningeal extension (11%). During first-line treatment, 18 patients (67%) had orbital radiotherapy. Median age at R/R was 10 years (ranges: 4-28) after a delay of 19 months from diagnosis (ranges: 3-40). Tumoral events were local relapses (22 cases), local progression (3 cases) or regional relapses (2 cases). Second-line treatments included chemotherapy (27 cases), radiotherapy (16 cases), surgery (exenteration; 8 cases) and metastasis/ nodal removal (3 cases). After a median follow-up of 99 months (range: 10-306), 4 patients died and 23 are in complete remission (CR) without treatment. One patient had subsequent relapse treated with exenteration and brachytherapy until a new tumour remission. Five-year event-free and overall survivals after first tumour event are, respectively, 84.4% (95% confidence interval: 71.5%-98.8%) and 85.8% (95% confidence interval: 72.1%-100.0%) CONCLUSION: R/R-oRMS is a rare situation. Second-line therapy is efficient in this location, sometime at the cost of lifesaving mutilating surgery. Second-line local therapy needs therefore to consider local radiotherapy if possible or complete wide surgery.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
---|---|
Enthalten in: |
Acta ophthalmologica - 99(2021), 3 vom: 16. Mai, Seite 334-341 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zloto, Ofira [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antineoplastic Agents |
---|
Anmerkungen: |
Date Completed 30.11.2021 Date Revised 30.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/aos.14596 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314067914 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314067914 | ||
003 | DE-627 | ||
005 | 20231225151930.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/aos.14596 |2 doi | |
028 | 5 | 2 | |a pubmed24n1046.xml |
035 | |a (DE-627)NLM314067914 | ||
035 | |a (NLM)32833335 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zloto, Ofira |e verfasserin |4 aut | |
245 | 1 | 0 | |a Second-line therapy in young patients with relapsed or refractory orbital rhabdomyosarcoma |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.11.2021 | ||
500 | |a Date Revised 30.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. | ||
520 | |a OBJECTIVE: Localized orbital rhabdomyosarcoma (oRMS) has an overall favourable prognosis with more than 90% of survival. Little is known about the best strategy in recurrent/refractory (R/R) cases. The purpose is to examine the characteristics of patients with R/R-oRMS, focusing on local therapy | ||
520 | |a METHODS: This is bicentric retrospective study. Analysis is of young patients (<30 years) with R/R-oRMS who were treated from 1989 to 2018 at the Institut Curie and Gustave Roussy Cancer Campus, France | ||
520 | |a RESULTS: Twenty-seven out of 162 patients (17%) with oRMS presented with R/R disease. 6 of these patients had alveolar RMS (22%), 3 of whom had initial parameningeal extension (11%). During first-line treatment, 18 patients (67%) had orbital radiotherapy. Median age at R/R was 10 years (ranges: 4-28) after a delay of 19 months from diagnosis (ranges: 3-40). Tumoral events were local relapses (22 cases), local progression (3 cases) or regional relapses (2 cases). Second-line treatments included chemotherapy (27 cases), radiotherapy (16 cases), surgery (exenteration; 8 cases) and metastasis/ nodal removal (3 cases). After a median follow-up of 99 months (range: 10-306), 4 patients died and 23 are in complete remission (CR) without treatment. One patient had subsequent relapse treated with exenteration and brachytherapy until a new tumour remission. Five-year event-free and overall survivals after first tumour event are, respectively, 84.4% (95% confidence interval: 71.5%-98.8%) and 85.8% (95% confidence interval: 72.1%-100.0%) CONCLUSION: R/R-oRMS is a rare situation. Second-line therapy is efficient in this location, sometime at the cost of lifesaving mutilating surgery. Second-line local therapy needs therefore to consider local radiotherapy if possible or complete wide surgery | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a biostatistics | |
650 | 4 | |a cancer | |
650 | 4 | |a oculoplastic | |
650 | 4 | |a orbit | |
650 | 4 | |a orbital rhabdomyosarcoma | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
700 | 1 | |a Minard-Colin, Veronique |e verfasserin |4 aut | |
700 | 1 | |a Boutroux, Helene |e verfasserin |4 aut | |
700 | 1 | |a Brisse, Herve J |e verfasserin |4 aut | |
700 | 1 | |a Levy, Christine |e verfasserin |4 aut | |
700 | 1 | |a Kolb, Frederic |e verfasserin |4 aut | |
700 | 1 | |a Bolle, Stephanie |e verfasserin |4 aut | |
700 | 1 | |a Carton, Matthieu |e verfasserin |4 aut | |
700 | 1 | |a Helfre, Sylvie |e verfasserin |4 aut | |
700 | 1 | |a Orbach, Daniel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Acta ophthalmologica |d 2008 |g 99(2021), 3 vom: 16. Mai, Seite 334-341 |w (DE-627)NLM171266315 |x 1755-3768 |7 nnns |
773 | 1 | 8 | |g volume:99 |g year:2021 |g number:3 |g day:16 |g month:05 |g pages:334-341 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/aos.14596 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 99 |j 2021 |e 3 |b 16 |c 05 |h 334-341 |